<table id="table8" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8	Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Tenofovir Disoproxil Fumarate<footnote>All interaction trials conducted in healthy volunteers.</footnote>
<sup>,</sup>
<footnote>Subjects received tenofovir DF 300 mg once daily.</footnote>
</caption>
<col align="left" valign="middle" width="20%"></col>
<col align="center" valign="middle" width="20%"></col>
<col align="center" valign="middle" width="10%"></col>
<col align="center" valign="middle" width="16%"></col>
<col align="center" valign="middle" width="17%"></col>
<col align="center" valign="middle" width="17%"></col>
<thead>
<tr stylecode="Botrule">
<th align="center" rowspan="2" stylecode="Lrule Rrule">Coadministered Drug</th>
<th rowspan="2" stylecode="Rrule">Dose of Coadministered Drug (mg)</th>
<th rowspan="2" stylecode="Rrule">N</th>
<th colspan="3" stylecode="Rrule">Mean % Change of Coadministered Drug Pharmacokinetic Parameters<footnote>Increase = ↑; Decrease = ↓; No Effect = ↔</footnote>
<br/>(90% CI)</th>
</tr>
<tr>
<th align="center" stylecode="Rrule">C<sub>max</sub>
</th>
<th stylecode="Rrule">AUC</th>
<th stylecode="Rrule">C<sub>min</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Lrule Rrule">Atazanavir<footnote>Reyataz Prescribing Information.</footnote>
</td>
<td stylecode="Botrule Rrule">400 once daily × 14 days</td>
<td stylecode="Botrule Rrule">34</td>
<td stylecode="Botrule Rrule">↓ 21<br/>(↓ 27 to ↓ 14)</td>
<td stylecode="Botrule Rrule">↓ 25<br/>(↓ 30 to ↓ 19)</td>
<td stylecode="Botrule Rrule">↓ 40<br/>(↓ 48 to ↓ 32)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">Atazanavir/ritonavir 300/100 once daily × 42 days</td>
<td stylecode="Rrule">10</td>
<td stylecode="Rrule">↓ 28<br/>(↓ 50 to ↑ 5)</td>
<td stylecode="Rrule">↓ 25<footnote id="t8f1">In HIV-infected patients, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C<sub>min</sub> values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.</footnote>
<br/>(↓ 42 to ↓ 3)</td>
<td stylecode="Rrule">↓ 23<footnoteref idref="t8f1"></footnoteref>
<br/>(↓ 46 to ↑ 10)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Didanosine<footnote>Videx EC Prescribing Information.  Subjects received didanosine enteric-coated capsules.</footnote>
</td>
<td stylecode="Rrule">250 once, simultaneously with tenofovir DF and a light meal<footnote>373 kcal, 8.2 g fat.</footnote>
</td>
<td stylecode="Rrule">33</td>
<td stylecode="Rrule">↓ 20<br/>(↓ 32 to ↓ 7)<footnote id="t8f2">Compared with didanosine (enteric-coated) 400 mg administered alone under fasting conditions.</footnote>
</td>
<td stylecode="Rrule">↔<footnoteref idref="t8f2"></footnoteref>
</td>
<td stylecode="Rrule">NA</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lopinavir</td>
<td stylecode="Rrule">Lopinavir/ritonavir 400/100 twice daily × 14 days</td>
<td stylecode="Rrule">24</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">Lopinavir/ritonavir 400/100 twice daily × 14 days</td>
<td stylecode="Rrule">24</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule">↔</td>
</tr>
</tbody>
</table>